Calidi Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Calidi Biotherapeutics generated cash of -$26,983,000, which is less than the previous year. Cash used in financing activities reached the amount of $29,044,000 last year. Net change in cash is therefore $1,577,000.
Cash Flow
| 2022 | -13.21M | -494K | 12.08M |
|---|---|---|---|
| 2023 | -26.98M | -478K | 29.04M |
CLDI Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 472K | 1.06M |
Operating activities | ||
Net income | -29.21M | -25.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 1.25M | 260K |
Stock-based compensation expense | 4.80M | 6.14M |
| Deferred income tax benefit | 4.80M | 6.14M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | -870 |
Inventories | 0 | 0 |
Accounts payable | -6.17M | 1.62M |
Cash generated by operating activities | -26.98M | -13.21M |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | -585K | -428K |
Acquisitions Net | 9K | 0 |
Cash generated by investing activities | -478K | -494K |
Financing activities | ||
Common Stock Issued | 2.76M | 10.76M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 899K | 1.38M |
Cash used in financing activities | 29.04M | 12.08M |
Net Change In Cash | 1.57M | -590.65K |
Cash at end of period | 2.04M | 472K |